北京赛升药业股份有限公司 第五届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开情况 证券代码：300485 证券简称：赛升药业 公告编号：2025-052 二、会议审议情况 经全体董事认真审议并表决，会议通过了以下议案： 北京赛升药业股份有限公司（以下简称"公司"）第五届董事会第十二次会 议于2025年12月26日在公司会议室召开，本次会议于2025年12月22日以通讯的方 式向所有董事送达了会议通知。应参与会议董事9名，实际参会董事9人，会议由 董事长马骉主持，公司高级管理人员列席了本次会议。本次会议的召开符合《中 华人民共和国公司法》等有关法律、行政法规、部门规章、规范性文件和《公司 章程》的规定，会议决议合法、有效。 北京赛升药业股份有限公司 经审议，董事会认为：本次公司向君元药业提供财务资助的展期，是基于对 君元药业的认可及后续发展的信心，为进一步支持君元药业的日常经营和业务发 展，符合公司的发展战略。本次财务资助展期是公司在不影响自身正常经营的前 提下进行的，风险处于可控制范围内，不会对公司的正常运作和日常经 ...

Group 1 - The biopharmaceutical sector increased by 0.18% on December 25, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] - Key stocks in the biopharmaceutical sector showed various performance, with Jindike (688670) rising by 4.66% to a closing price of 22.45 [1] Group 2 - The biopharmaceutical sector experienced a net outflow of 307 million yuan from institutional investors, while retail investors saw a net inflow of 359 million yuan [2] - Notable declines included Te Bao Biological (688278), which fell by 3.14% to a closing price of 80.90 [2] - The trading volume and turnover for various stocks in the sector varied significantly, with Wan Ze Co. (000534) achieving a turnover of 488 million yuan [1][2] Group 3 - Jindike (688670) had a net inflow of 25.23 million yuan from institutional investors, while retail investors had a net outflow of 23.95 million yuan [3] - Other stocks like Zhi Xiang Jin Tai (688443) and Shen Zhou Cell (688520) also showed mixed net inflows and outflows from different investor categories [3] - The overall trend indicates a divergence in investor sentiment, with institutional investors pulling back while retail investors increased their positions [2][3]

证券日报网讯12月15日，赛升药业（300485）在互动平台回答投资者提问时表示，截至2025年12月10 日，公司股东户数为35036户。 ...

Group 1 - The core point of the article is that Sai Sheng Pharmaceutical has received a notice from the National Medical Products Administration regarding the acceptance of its application for the production registration of Dapagliflozin Metformin Extended-Release Tablets [2] Group 2 - The announcement was made on the evening of December 4, indicating a significant step in the company's product development process [2] - The product in question, Dapagliflozin Metformin Extended-Release Tablets, is aimed at the domestic market, highlighting the company's focus on local production and regulatory compliance [2] - This development may enhance the company's portfolio in the diabetes treatment segment, potentially leading to increased market share and revenue growth [2]

Group 1 - China Pacific Insurance has received approval from the financial regulatory authority for Wang Yuhua to serve as a director [1] - Shanghai Bank announced that the regulatory authority has approved Chen Lei's qualification as vice president [2] - Shanghai HuGong has decided to terminate the "Aerospace Equipment Manufacturing Base" fundraising project due to significant changes in project feasibility [3] Group 2 - Dongwang Times plans to reduce its stake by up to 1.20% through share sales [4] - Zhinancun intends to increase its capital by 100 million yuan in its wholly-owned subsidiary, Maigao Securities [5] - Jinxinnong reported a sales revenue of 115 million yuan from pig sales in November [6] Group 3 - Tiantan Biological has completed the Phase III clinical trial of its human prothrombin complex, showing good efficacy and safety for hemophilia B patients [7] - Beijete's subsidiary has signed a framework agreement for equity acquisition to gain control of Yunnan Wenye Nonferrous Metals [8] - Zhongsheng Pharmaceutical's RAY1225 injection has received approval for a new clinical trial indication for treating metabolic-associated fatty liver disease [9] Group 4 - Enhua Pharmaceutical's hydrochloride sulpiride tablets have passed the consistency evaluation for generic drugs [10] - Shenkong Co. plans to invest 60 million yuan in a semiconductor industry fund [11] - Lianhuan Pharmaceutical's subsidiary has received approval for its drug to pass the consistency evaluation for generic drugs [12] Group 5 - Dazhong Transportation has received approval to issue debt financing tools totaling 4.5 billion yuan [13] - Jintian Titanium Industry plans to invest 50 million yuan in an industry merger and acquisition fund [14] - Changchun Gas has committed over 1.7 billion yuan to gas facility upgrades [15] Group 6 - Laimei Pharmaceutical's innovative anti-cancer drug "Nano Carbon Iron" has received approval for clinical trials [16] - Longquan Co. has signed supply contracts worth approximately 50.76 million yuan for nuclear power components [17] - Igor plans to distribute a cash dividend of 1 yuan per 10 shares [18] Group 7 - Xingfa Group's subsidiary has signed a processing agreement for 80,000 tons of lithium iron phosphate [20] - Yunjigroup's director Wang Wanfeng has resigned for personal reasons [21] - Saiseng Pharmaceutical's application for the listing of a new drug has been accepted by the regulatory authority [22] Group 8 - Xinhua Medical has obtained registration certificates for two new medical devices [23] - Chaoying Electronics plans to invest 100 million USD in its Thai subsidiary for an AI circuit board expansion project [24] - Suzhou Planning's application to acquire 100% of Dongjin Aviation has been accepted by the Shenzhen Stock Exchange [25]

Core Viewpoint - The announcement by Sai Sheng Pharmaceutical regarding the acceptance of the production registration application for Dapagliflozin Metformin Extended-Release Tablets marks a significant step in expanding its product portfolio in the diabetes treatment market [1] Group 1: Company Developments - Sai Sheng Pharmaceutical's subsidiary, Sai Er Biological, has received a notice from the National Medical Products Administration regarding the acceptance of the production registration application for Dapagliflozin Metformin Extended-Release Tablets [1] - The combination of SGLT-2 inhibitor Dapagliflozin and Metformin is developed by AstraZeneca and was approved by the FDA in 2014 [1] Group 2: Industry Insights - SGLT-2 inhibitors function through a non-insulin-dependent mechanism, reducing glucose reabsorption in the kidneys and promoting glucose excretion through urine, which helps lower blood sugar levels [1] - The combination of SGLT-2 inhibitors with Metformin has shown better glycemic control and lower side effects [1]

Core Viewpoint - The company has received a notice from the National Medical Products Administration regarding the acceptance of the registration application for the domestic production of Dapagliflozin Metformin Extended-Release Tablets [1] Group 1: Company Developments - The subsidiary Beijing Sai'er Biological Pharmaceutical Co., Ltd. has received the acceptance notice for the drug registration application [1] - Dapagliflozin and Metformin combination tablets were developed by AstraZeneca and were approved by the FDA in 2014 [1] Group 2: Industry Insights - SGLT-2 inhibitors work through a non-insulin-dependent mechanism, reducing glucose reabsorption in the kidneys and promoting glucose excretion through urine [1] - The combination of SGLT-2 inhibitors with Metformin has shown better glycemic control and lower side effects [1]

Core Viewpoint - The company has received a production registration approval notice from the National Medical Products Administration for its product, Dapagliflozin Metformin Extended-Release Tablets, indicating a significant step towards market entry in China [1] Group 1: Company Developments - Subsidiary Beijing Sair Biological Pharmaceutical Co., Ltd. has received the acceptance notice for the drug registration application [1] - The combination of SGLT-2 inhibitor Dapagliflozin and Metformin is expected to provide better glycemic control with fewer side effects [1] Group 2: Industry Context - Dapagliflozin and Metformin combination was developed by AstraZeneca and received FDA approval in 2014 [1] - The SGLT-2 inhibitors work through a non-insulin-dependent mechanism, reducing glucose reabsorption in the kidneys and promoting glucose excretion [1]

证券代码：300485 证券简称：赛升药业 公告编号：2025-051 北京赛升药业股份有限公司 关于子公司收到药品注册上市许可申请受理通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 北京赛升药业股份有限公司（以下简称"公司"）子公司北京赛而生物药业 有限公司（以下简称"赛而生物"）近日收到了国家药品监督管理局下发的达格 列净二甲双胍缓释片境内生产药品注册上市许可申请的《受理通知书》。现将相 关信息公告如下： 一、《受理通知书》主要内容 定予以受理。 受理号：CYHS2504***、CYHS2504*** （二）申请单位：北京赛而生物药业有限公司 申请事项：境内生产药品注册上市许可 产品名称：达格列净二甲双胍缓释片（Ⅱ） 规 格：达格列净2.5mg（以C21H25C106计）和盐酸二甲双胍1000mg 根据《中华人民共和国行政许可法》第三十二条的规定，经审查，决 定予以受理。 受理号：CYHS2504*** （三）申请单位：北京赛而生物药业有限公司 申请事项：境内生产药品注册上市许可 （一）申请单位：北京赛而生物药业有限公司 申请事项：境内生产药 ...

Core Viewpoint - The announcement indicates that the subsidiary of the company, Sai Er Biological, has received a notice of acceptance for the registration application of Dapagliflozin Metformin Extended-Release Tablets from the National Medical Products Administration, marking a significant step in the drug's approval process [1] Group 1 - The registration application involves four specifications (I, II, III, IV) for the drug [1] - The compound tablet was developed by AstraZeneca and was approved for marketing in the United States in 2014, with approval in China occurring in June 2023 [1] - The acceptance of the application means the product is entering the registration review stage, which is expected to have no significant impact on the company's recent performance [1] Group 2 - If the review is successfully passed, it will enrich the product pipeline of Sai Er Biological [1] - The timeline and outcome for drug registration approval remain uncertain [1]